Table 4.
Citrate synthase activity, and complex I- and II-dependent oxidative phosphorylation in PBMC and CK in plasma of CFS patients and controls before CPET1 and CPET2&
| CPET1 | CPET2 | |||
|---|---|---|---|---|
| Patients n = 15 | Controls n = 15 | Patients n = 15 | Controls n = 15 | |
| Citrate synthase (CS) U/g protein | 135 ± 61 | 132 ± 17 | 128 ± 20 | 154 ± 51 |
| ATP synthesis via Complex I nmol/(0.5 h. mg protein) | 7.1 ± 3.1 | 7.8 ± 2.8 | 6.7 ± 4.8 | 9.5 ± 5.7 |
| ATP synthesis via Complex I nmol/(0.5 h. U CS) | 54 ± 19 | 58 ± 21 | 54 ± 34 | 61 ± 26 |
| ATP synthesis via Complex II nmol/(0.5 h. mg protein) | 7.8 ± 5.0 | 8.2 ± 2.8 | 6.8 ± 4.9 | 8.9 ± 5.3 |
| ATP synthesis via Complex II nmol/(0.5 h. U CS) | 58 ± 22 | 60 ± 26 | 54 ± 36 | 58 ± 27 |
| CK in plasma U/L | 70 ± 25 | 83 ± 35 | 64 ± 22 | 96 ± 63 |
&Data are presented as mean ± SD
There were no statistically significant differences between patients and controls at CPET1 or 2 (according to multivariate ANOVA), or between CEPT1 and 2 for patients or for controls (according to repeated measures ANOVA)